Logo image of HBP.CA

HELIX BIOPHARMA CORP (HBP.CA) Stock Price, Quote, News and Overview

TSX:HBP - Toronto Stock Exchange - CA4229102088 - Common Stock - Currency: CAD

0.9  -0.02 (-2.17%)

HBP.CA Quote, Performance and Key Statistics

HELIX BIOPHARMA CORP

TSX:HBP (2/3/2025, 7:00:00 PM)

0.9

-0.02 (-2.17%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.35
52 Week Low0.5
Market Cap44.12M
Shares49.02M
Float42.50M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-03 1996-06-03


HBP.CA short term performance overview.The bars show the price performance of HBP.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

HBP.CA long term performance overview.The bars show the price performance of HBP.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of HBP.CA is 0.9 CAD. In the past month the price decreased by -10%. In the past year, price decreased by -10%.

HELIX BIOPHARMA CORP / HBP Daily stock chart

HBP.CA Latest News and Analysis

News Image
3 years ago - Jerzy Wilczewski

Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.

VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Company") (TSX: HBP) at a price of $0.26 per Common Share by way of non-brokered private placement for an aggregate subscription price of C$2,002,000 (the "Private Placement"). As a result of the closing of the Private Placement, Mr. Wilczewski

News Image
3 years ago - Helix BioPharma Corp.

Helix Biopharma Corp. Closes Private Placement

RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per common

News Image
3 years ago - Helix BioPharma Corp.

Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results

RICHMOND HILL, ON / ACCESSWIRE / December 15, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 first quarter results for the period ending October 31, 2021. OVERVIEW The Company reported a net loss and total comprehensive loss for the

HBP.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
FRX.CA FENNEC PHARMACEUTICALS INC N/A 247.78M
BCT.CA BRIACELL THERAPEUTICS CORP N/A 236.47M
EDT.CA SPECTRAL MEDICAL INC N/A 166.88M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 163.85M
TH.CA THERATECHNOLOGIES INC N/A 105.75M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 99.26M
COV.CA COVALON TECHNOLOGIES LTD 28.09 84.67M
ONC.CA ONCOLYTICS BIOTECH INC N/A 84.01M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 79.27M
MBX.CA MICROBIX BIOSYSTEMS INC 16.5 66.59M
SVA.CA SERNOVA CORP N/A 55.07M
MDCX.CA MEDICUS PHARMA LTD N/A 41.77M

About HBP.CA

Company Profile

HBP logo image Helix BioPharma Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 7 full-time employees. Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The firm is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.

Company Info

HELIX BIOPHARMA CORP

Bay Adelaide Centre - North Tower 40, Temperance Street, Suite 2700 Toronto

TORONTO ONTARIO L4B 3J9 CA

CEO: Heman Chao

Employees: 9

Company Website: https://www.helixbiopharma.com/

Investor Relations: http://www.helixbiopharma.com/investor-relations/

Phone: 16046842181

HBP.CA FAQ

What is the stock price of HBP.CA?

The current stock price of HBP.CA is 0.9 CAD.


What is the symbol for HELIX BIOPHARMA CORP stock?

The exchange symbol of HELIX BIOPHARMA CORP is HBP and it is listed on the Toronto Stock Exchange exchange.


On which exchange is HBP.CA stock listed?

HBP.CA stock is listed on the Toronto Stock Exchange exchange.


Is HBP.CA a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for HBP.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of HBP.CA.


Does HBP.CA stock pay dividends?

HBP.CA does not pay a dividend.


What is the Price/Earnings (PE) ratio of HBP.CA?

HBP.CA does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).


HBP.CA Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to HBP.CA. When comparing the yearly performance of all stocks, HBP.CA turns out to be only a medium performer in the overall market: it outperformed 41.3% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

HBP.CA Financial Highlights

Over the last trailing twelve months HBP.CA reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS decreased by -215.04% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -2257.73%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%7.5%
Sales Q2Q%N/A
EPS 1Y (TTM)-215.04%
Revenue 1Y (TTM)N/A

HBP.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to HBP.CA. The Buy consensus is the average rating of analysts ratings from 5 analysts.


Ownership
Inst OwnersN/A
Ins Owners13.3%
Short Float %N/A
Short RatioN/A
Analysts
Analysts80
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A